Acute myeloid leukemia stem cells from genomic and immunological perspectives

DOI Web Site PubMed
  • GOYAMA Susumu
    Division of Molecular Oncology, Graduate School of Frontier Sciences, The University of Tokyo

Bibliographic Information

Other Title
  • AML幹細胞
  • AML幹細胞 : ゲノム学および免疫学との融合
  • AML カンサイボウ : ゲノムガク オヨビ メンエキガク ト ノ ユウゴウ
  • —ゲノム学および免疫学との融合—

Search this article

Abstract

<p>Evidence of human leukemia stem cells (LSCs) in acute myeloid leukemia (AML) was first reported nearly a quarter century ago through the identification of rare engrafting cell subpopulations in patient-derived xenograft assays. Since then, studies have revealed diverse characteristics of AML stem cells. Initiating mutations convert normal hematopoietic stem cells (HSCs) to pre-leukemic HSCs. The repopulation advantage of pre-leukemic HSCs over normal HSCs leads to clonal evolution. Acquisition of additional mutations in pre-leukemic HSCs results in the development of AML composed of genetically distinct subclones. Each subclone contains LSCs with unique characteristics, and these LSCs contribute to therapeutic resistance and relapse. Interestingly, some LSCs can escape from antitumor immune responses, thereby survive the treatment. This article summarizes recent advances in the field of LSC biology from genomic and immunological perspectives.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 61 (9), 1130-1137, 2020

    The Japanese Society of Hematology

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top